Trehalose

D-(+)-Trehalose (Mycose) can inhibit the decomposition of collagen, so it can be used to improve osteoporosis.

6-Trehalose monooleate is a glycolipid employed in creating lipid nanoparticles (LNPs) for ex vivo delivery of immunosuppressants. In a tape-stripping test with isolated rabbit ear skin, LNPs with 6-trehalose monooleate encapsulating cyclosporin A predominantly accumulate in the stratum corneum rather than the epidermis and dermis. Additionally, 6-trehalose monooleate serves as an anti-aggregation agent for proteins.

Trehalose C12 (α-D-Glucopyranosyl-α-D-glucopyranoside monododecanoate) is a non-reducing disaccharide utilized for its amphiphilic properties as an emulsifier, surfactant, encapsulating material, and in biochemical research on cellular processes and membrane interactions.

Trehalose C14 is a surfactant.

Trimethylsilyl-D-(+)-trehalose is a reagent used in biochemical reactions.

Trehalase, Microorganism (EC 3.2.1.28), is an enzyme that effectively degrades trehalose in certain bacteria. It serves as a biomarker for acute kidney injury resulting from proximal tubule damage.

Dimethyldioctadecylammonium (DDA) is a cationic amphipathic lipid. DDA liposomes containing an Ag85B-ESAT-6 antigen induce antigen deposition at an intramuscular or subcutaneous injection site in mice, increasing immune cell exposure to the antigen. In a guinea pig model of M. tuberculosis infection, spleen bacterial load is reduced and lung and spleen lesion numbers are decreased when the mycobacterial lipid antigens Ac2SGL and PIM2 are administered in liposomes comprised of DDA and a synthetic analog of the mycobacterial cord factor trehalose 6,6-dibehenate (TDB). DDA has also been used in the study of lipid bilayer dynamics.